IQVIA Institute for Human Data Science Reports

Achieving Sustainable Levels of Biosimilar Competition in Europe

Interactions between patient organizations and life sciences companies.

This oncology research from the IQVIA Institute profiles the current state of research and development in oncology, including key mechanisms, targets and cancer types being investigated as well as pointing to some novel areas which are only just emerging. The research also looks at metrics of clinical development productivity and the progress being made to improve representativeness of race and ethnicity in clinical trial populations.

Evidence-based research and dissemination of findings remain a key foundation to advance our collective understanding and interpretation of events, and to take actions that will shape the future for all stakeholders. This annual trend report is intended to contribute to that understanding.

The purpose of this report is to summarize the results of research into the nature and use of illegal online pharmacies (IOPs) over recent years and the impact this has on public health and the operation of the distribution system. The research draws on a novel methodology developed by IE University in Madrid, Spain, and used by Translucent Datalab, a spin-off from IE University, to profile the network of IOPs that are being accessed from the U.S. and used to order prescription medicines.

This report assesses the trends in new drug approvals and launches, overall pipeline activity in terms of actively researched medicines, and the number of initiated clinical trials. It also profiles the state of R&D funding and the activity of companies of different types, and the results of research are compared to the input effort in a Clinical Development Productivity Index.

In this annual global trend report, the IQVIA Institute quantifies the impact of various dynamics and examines the spending and usage of medicines in 2022 and the outlook to 2027, globally and for specific therapy areas and countries. This report is intended to provide a foundation for meaningful discussion about the value, cost, and role of medicines over the next five years in the context of overall healthcare spending.

The purpose of the research incorporated in this report is to measure the progress that has been made in increasing participation by racial and ethnic groups – with a principal focus on Black/African Americans and Hispanics – in clinical trials.

In this report, the IQVIA Institute assesses the current state of the biologics market in the United States and share of the market facing biosimilar competition. Factors impacting biosimilar uptake, including reimbursement and provider type, and the impact of biosimilars on molecule volume and price are evaluated. Historic biosimilar trends are utilized to provide potential future biosimilar spending and savings scenarios.